Last update: March 29, 2015

βαλσαρτάνη

Low Risk for breastfeeding


Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.

At latest update, relevant published data on excretion into breast milk were not found.

A high protein-binding capacity makes excretion into breast milk unlikely. In addition, a low oral bioavailability makes difficult the absorption towards the infant's plasma from ingested milk, except in prematures or newborns who may show an increased absorption.

Case report of kidney function impairment of a baby whose mother had taken Telmisartan in pregnancy.

Until more data on this medication is available, safer alternative drugs are preferred, especially in premature babies or during the neonatal period.

Should an ARA-II medication (Sartan type) be necessary, the associated risk may be decreased by choosing the one with a favorable pharmacokinetics (shorter half-life elimination time and lower bioavailability) like Eprosartan and Losartan

Alternatives

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

βαλσαρτάνη is also known as Valsartan. Here it is a list of alternative known names::


Group

βαλσαρτάνη belongs to this group or family:

Tradenames

Main tradenames from several countries containing βαλσαρτάνη in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 23 - 39 %
Molecular weight 436 daltons
Protein Binding 97 %
VD 0,24 l/Kg
Tmax 2 - 4 hours
T1/2 6 - 9 hours

References

  1. Malachias MV, Figueiredo CE, Sass N, Antonello IC, Torloni MR, Bortolotto MRF L. 7th Brazilian Guideline of Arterial Hypertension: Chapter 9 - Arterial Hypertension in pregnancy Arq Bras Cardiol. 2016 Abstract Full text (link to original source) Full text (in our servers)
  2. Rowe H, Baker T, Hale TW. Maternal medication, drug use, and breastfeeding. Pediatr Clin North Am. 2013 Feb;60(1):275-94. Abstract
  3. AEMPS. Valsartán. Ficha técnica. 2009 Full text (in our servers)
  4. MHRA. Valsartan. Drug Summary. 2009 Full text (in our servers)
  5. Tamargo j, Caballero R, Gómez R, Núñez L, Vaquero M y Delpón E. Características farmacológicas de los ARA-II. ¿Son todos iguales?. Rev Esp Cardiol Supl. 2006;6:10C-24C. 2006 Full text (in our servers)
  6. Pietrement C, Malot L, Santerne B, Roussel B, Motte J, Morville P. Neonatal acute renal failure secondary to maternal exposure to telmisartan, angiotensin II receptor antagonist. J Perinatol. 2003 Abstract Full text (link to original source) Full text (in our servers)

Total visits

893

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by La Liga de la Leche, España from Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM